other material
confidence high
sentiment neutral
materiality 0.60
Avalo Therapeutics enters $75M ATM equity offering with TD Cowen, terminates prior Oppenheimer facility
Avalo Therapeutics, Inc.
- Entered Sales Agreement with TD Cowen for at-the-market offering of up to $75M in common stock.
- Commission to TD Cowen is up to 3% of gross proceeds from sales.
- Terminated prior ATM agreement with Oppenheimer (originally $50M) effective June 4, 2025; no penalties.
- Offering is made under existing effective S-3 registration statement (File No. 333-271225).